Hepatitis B test kit Aptima®

HBVserumplasma

Deliver trusted results with dual targets across a wide linear range and all major HBV genotypes. The Aptima® HBV Quant Assay is a molecular HBV treatment management assay with dual-target design. It helps providers guide treatment management for patients with chronic hepatitis B infection who are undergoing antiviral therapy. Quantitation Across Genotypes Validated performance across HBV genotypes A – H, with added tolerance to mutations. Unique Design Allows laboratorians to deliver trusted results from baseline throughout treatment despite low or high viral loads. Quantitate with Confidence The Aptima HBV Quant assay utilizes a unique dual-target design, providing accuracy in the face of high and low viral loads, genotype variation and mutations, so you can deliver trusted results from baseline measurement throughout treatment. Unique design. Ultimate confidence. The Aptima HBV Quant assay is a dual-target molecular assay for HBV treatment management.1 Targets 2 highly conserved regions in the polymerase and surface genes Provides added tolerance to mutations in the HBV genome Ensures accurate quantitation over a wide linear range Claim Quant LoD 4.8 IU/mL in plasma 5.9 IU/mL in serum LLoQ 6 IU/mL in plasma 8 IU/mL in serum Methodology RT-TMA